05:25 AM EDT, 10/14/2026 (MT Newswires) -- SciBase Holding's (SCIB.ST) Nevisense secured its first positive medical policy from Highmark Blue Cross Blue Shield in the US, broadening its reach across dermatology practices and patients in the country. The decision allows the use of the dermatology-focused medical technology company's medical device to move to covered care through a private insurer from a cash-pay model, according to a Wednesday release. SciBase said the coverage gives it the opportunity to expand its reach in the US market.

Disclaimer:This article represents the opinion of the author only. It does not represent the opinion of Webull, nor should it be viewed as an indication that Webull either agrees with or confirms the truthfulness or accuracy of the information. It should not be considered as investment advice from Webull or anyone else, nor should it be used as the basis of any investment decision.